Topics
Glioblastoma | Treatment | Chemotherapy | Temozolomide | Tumor treating fields
Home > Publications > Topics > Glioblastoma > Treatment > Chemotherapy > Temozolomide > Tumor treating fields
2024
Goldlust SA, Singer S, Cappello LA, AlMekkawi AK, Lee KD, Ingenito
AC, Lewis BE, Nyirenda T, Azmi H, Kaptain GJ.
Phase
1 study of concomitant tumor treating fields and temozolomide
chemoradiation for newly diagnosed glioblastoma.
Neurooncol
Adv. 2024 Jul 29;6(1):vdae129. doi:
10.1093/noajnl/vdae129. PMID:
39211521. Interventional study.ˍ
2025
Chen D, Le SB, Ghiaseddin AP, Manektalia H, Li M, O'Dell A, Rahman
M, Tran DD.
Efficacy and safety of
adjuvant TTFields plus pembrolizumab and temozolomide in newly
diagnosed glioblastoma: A phase 2 study.
Med.
2025 Jun 3:100708. doi:
10.1016/j.medj.2025.100708. PMID:
40466642. Interventional study. ˍ
2026
Limon D, Bokstein F, Blumenthal
DT, Ram Z, Grossman R.
Prospective
randomized trial of tumor-treating fields with chemoradiation in
newly diagnosed glioblastoma.
Neurooncol
Adv. 2026 Apr
24;8(1):vdag106. doi:
10.1093/noajnl/vdag106. PMID:
42239656. Trial
registration ID:
NCT03869242.
ˍ
Zhu W, Rao J, Hu G, Wang R, Luo X, Li Q.
Tumor
treating fields plus temozolomide maintenance after
radiochemotherapy in Chinese grade 4 gliomas: Efficacy and
predictive biomarkers.
Neurooncol
Adv. 2026 Jul 23;8(1):vdag194. doi:
10.1093/noajnl/vdag194. PMID:
42630691. ˍ